NCT05922254Completed
Combined Effects of ACBT and AUTOGENIC DRAINAGE in Patients With Chronic Obstructive Pulmonary Disease
Combined Effects of Active Cycle of Breathing Technique and Autogenic Drainage in Patients With Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 27 Dec 2023
Brief summary (registry, in English)
A randomised controlled trial will be conducted with COPD patients as its target population. There will be 40 individuals for both the control group and the intervention group. Group A is a control group while Group B is an experimental group (20 participants on Group A and 20 on group B). The baseline treatment for both groups were pursed lip breathing and ACBT. On the other hand, group B experimental group will also undergo (pursued lip breathing and ACBT) with autogenic drainage. Group A session lasts for 30 minutes and Group B session lasts for 45 minutes. There is only one session per day. There is a three session in a week for 4 weeks. Measurements are made of dyspnea, oxygen saturation, peak expiratory flow rate, pulse rate and fatigue both before and after the treatment, data were recorded. Participants in the trial must have mild to moderate COPD (GOLD Criteria) and be between the ages of 40 to 60 years. Data from Sheikh Zayed Hospital, Rahim Yar Khan will be collected. Follow-up for both completed tasks and changes in pulmonary status will be evaluated after 4 weeks. Modified Borg Dyspnea (RPE) Scale, Breathlessness, Cough and Sputum Scale (BCSS), Fatigue Severity Scale or Visual Analogue Scale, Peak flow meter, Oximeter will be used to measure the outcomes. Data will be analysed using the SPSS 21.0 Statistical Software
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 6 Jun 2023
- Start date
- 15 Jun 2023
- Primary completion date
- 15 Sept 2023
- Lead sponsor
- Riphah International University
- Diseases
- COPD
- NCT number
- NCT05922254
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 15 Jun 2023 to the primary completion date, 15 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any recent surgery
Other illness
- Cardiovascular impairment
- Systemic illness
- Angina
- Uncontrolled diabetes and hypertension
Other
- Patients having progressive respiratory muscle weakness (Mysthenia Gravis)
- TB
- Non-cooperative Patients
Who the study is looking for
- Both genders (Male and Female)
- Age 40 to 60 years
- Mild to moderate COPD (According to GOLD Criteria)
- Patient is bilingual.
Age in the registry: 40 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheikh Zayed Hospital, Coordinator of this site? Confirm its status | Rahim Yar Khan | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.